No Data
No Data
Buy Rating Justified for BridgeBio Pharma Amidst Promising Long-Term Market Prospects for ATTR-CM Treatments
BridgeBio Pharma Price Target Raised to $45.00/Share From $35.00 by JP Morgan
BridgeBio Pharma Price Target Raised to $45.00/Share From $35.00 by JP Morgan
BridgeBio Pharma Is Maintained at Overweight by JP Morgan
BridgeBio Pharma Is Maintained at Overweight by JP Morgan
Express News | JP Morgan Maintains Overweight on BridgeBio Pharma, Raises Price Target to $45
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Jazz Pharmaceuticals (JAZZ)
BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases a
No Data